CABOMETYX®▼ (cabozantinib) is a prescription-only medicine indicated for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.

For more information on this product please visit the electronic Medicines Compendium (eMC) where you will find links to the Patient Information Leaflets (PIL) and Summary of Product Characteristics (SPC)

You can also find out further information from your Healthcare Professional.